NCT05884333View on ClinicalTrials.gov

Cord Blood Transplant in Adults With Blood Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

May 22, 2028

Study Completion Date

May 22, 2028

Conditions
Acute Myelogenous Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Chronic Myelogenous Leukemia (CML)Myelodysplastic Syndromes (MDS)Myeloproliferative DisorderNon-Hodgkin's Lymphoma
Interventions
DRUG

Conditioning Chemotherapy

Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 \& -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours \& Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).

BIOLOGICAL

Cord blood graft

The double-unit CB graft will be infused on day 0 per standard practice.

Trial Locations (1)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER